MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - indian pharma
- IPCA LABS - ADCOCK INGRAM (S. Africa)
IPCA LABS vs ADCOCK INGRAM (S. Africa) - Comparison Results
IPCA LABS 
Change
Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More
ADCOCK INGRAM (S. Africa)
Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
Financials
 IPCA LABS  ADCOCK INGRAM |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| IPCA LABS Mar-18 |
ADCOCK INGRAM Jun-14 |
IPCA LABS/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 695 | 349 | - | |
| Low | Rs | 400 | 252 | - | |
| Sales per share (Unadj.) | Rs | 260.2 | 104.0 | - | |
| Earnings per share (Unadj.) | Rs | 19.0 | -26.2 | - | |
| Cash flow per share (Unadj.) | Rs | 33.1 | -21.7 | - | |
| Dividends per share (Unadj.) | Rs | 1.00 | 0 | - | |
| Dividend yield (eoy) | % | 0.2 | 0 | - | |
| Book value per share (Unadj.) | Rs | 213.0 | 81.6 | - | |
| Shares outstanding (eoy) | m | 126.20 | 168.78 | - | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 2.1 | 2.9 | 72.8% | |
| Avg P/E ratio | x | 28.9 | -11.5 | -251.4% | |
| P/CF ratio (eoy) | x | 16.6 | -13.9 | -119.6% | |
| Price / Book Value ratio | x | 2.6 | 3.7 | 69.7% | |
| Dividend payout | % | 5.3 | 0 | - | |
| Avg Mkt Cap | Rs m | 69,120 | 50,764 | 136.2% | |
| No. of employees | `000 | 13.3 | 4.3 | 308.7% | |
| Total wages/salary | Rs m | 7,359 | 3,186 | 231.0% | |
| Avg. sales/employee | Rs Th | 2,477.4 | 4,086.8 | 60.6% | |
| Avg. wages/employee | Rs Th | 555.2 | 742.1 | 74.8% | |
| Avg. net profit/employee | Rs Th | 180.6 | -1,029.8 | -17.5% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 32,836 | 17,545 | 187.2% | |
| Other income | Rs m | 418 | 123 | 340.2% | |
| Total revenues | Rs m | 33,254 | 17,668 | 188.2% | |
| Gross profit | Rs m | 4,505 | -3,040 | -148.2% | |
| Depreciation | Rs m | 1,777 | 757 | 234.7% | |
| Interest | Rs m | 240 | 475 | 50.5% | |
| Profit before tax | Rs m | 2,905 | -4,150 | -70.0% | |
| Minority Interest | Rs m | 0 | -12 | 0.0% | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 511 | 259 | 197.1% | |
| Profit after tax | Rs m | 2,394 | -4,421 | -54.2% | |
| Gross profit margin | % | 13.7 | -17.3 | -79.2% | |
| Effective tax rate | % | 17.6 | -6.2 | -281.5% | |
| Net profit margin | % | 7.3 | -25.2 | -28.9% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 19,455 | 12,850 | 151.4% | |
| Current liabilities | Rs m | 10,076 | 7,230 | 139.4% | |
| Net working cap to sales | % | 28.6 | 32.0 | 89.2% | |
| Current ratio | x | 1.9 | 1.8 | 108.6% | |
| Inventory Days | Days | 98 | 111 | 88.3% | |
| Debtors Days | Days | 67 | 124 | 54.0% | |
| Net fixed assets | Rs m | 20,260 | 7,490 | 270.5% | |
| Share capital | Rs m | 252 | 81 | 309.9% | |
| Net worth | Rs m | 26,886 | 13,771 | 195.2% | |
| Long term debt | Rs m | 2,340 | 4,839 | 48.4% | |
| Total assets | Rs m | 41,173 | 26,014 | 158.3% | |
| Interest coverage | x | 13.1 | -7.7 | -169.4% | |
| Debt to equity ratio | x | 0.1 | 0.4 | 24.8% | |
| Sales to assets ratio | x | 0.8 | 0.7 | 118.2% | |
| Return on assets | % | 6.4 | -15.2 | -42.2% | |
| Return on equity | % | 8.9 | -32.1 | -27.7% | |
| Return on capital | % | 10.8 | -19.8 | -54.3% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 3,411 | 1,498 | 227.8% | |
| From Investments | Rs m | -1,354 | -460 | 294.5% | |
| From Financial Activity | Rs m | -1,304 | 4,392 | -29.7% | |
| Net Cashflow | Rs m | 753 | 5,430 | 13.9% | |
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 4.82 Rs / ZAR
Compare IPCA LABS With: MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Compare IPCA LABS With: J.B.CHEMICALS DISHMAN PHARMA ALEMBIC LTD FULFORD INDIA NOVARTIS
|
| |
Today's Market
Sensex Ends 248 Points Higher; Power and Metal Stocks Witness Buying(Closing)
Indian share markets continued their momentum and ended their day on a strong note today. Gains were largely seen in the power sector, metal sector, and capital goods sector.
Related Views On News
IPCA LABS Announces Quarterly Results (3QFY19); Net Profit Up 51.7% (Quarterly Result Update)
Feb 14, 2019 | Updated on Feb 14, 2019For the quarter ended December 2018, IPCA LABS has posted a net profit of Rs 2 bn (up 51.7% YoY). Sales on the other hand came in at Rs 9 bn (up 10.3% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.
IPCA LABS Announces Quarterly Results (2QFY19); Net Profit Up 24.1% (Quarterly Result Update)
Nov 15, 2018 | Updated on Nov 15, 2018For the quarter ended September 2018, IPCA LABS has posted a net profit of Rs 1 bn (up 24.1% YoY). Sales on the other hand came in at Rs 10 bn (up 15.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
The Power of 5 Minutes (The 5 Minute Wrapup)
Jun 16, 2017Here's what you can expect from The 5 Minute Wrapup in the coming months and years.
More Views on NewsMost Popular
My Top 7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)
May 16, 2019Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.
3 Stocks to Bet on to Become a 'Dividend Millionaire'(Profit Hunter)
May 14, 2019As markets continue to rattle amid earning season, upcoming elections, volatile crude price and US China trade war, it's a great idea to add some stability to your portfolio by adding dividend stocks.
Indian Steel: The Perfect Multibagger Opportunity(Profit Hunter)
May 17, 2019A structurally strong Indian Steel Industry will help India achieve 8%+ GDP growth in the coming years.
My Top 7 Stocks to Buy as Modi Returns to Power(The 5 Minute Wrapup)
May 23, 2019The Modi government is all set to come back to power. With a stable government at the centre, how should you play the stock market?
What Makes TVS Srichakra and CCL Products a Cut Above the Rest?(The 5 Minute Wrapup)
May 17, 2019Despite the commodity nature of their businesses, these two stocks have rewarded shareholders well.
More|
| |
IPCA LABS SHARE PRICE
May 27, 2019 (Close)
TRACK IPCA LABS
- Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON IPCA LABS
IPCA LABS 5-YR ANALYSIS
COMPARE IPCA LABS WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.